Protocol
Using human iPSC-derived kidney organoids to decipher SARS-CoV-2 pathology on single cell level

We describe a protocol for single-cell RNA sequencing of SARS-CoV-2-infected human induced pluripotent stem cell (iPSC)-derived kidney organoids. After inoculation of kidney organoids with virus, we use mechanical and enzymatic disruption to obtain single cell suspensions. Next, we process the organoid-derived cells into sequencing-ready SARS-CoV-2-targeted libraries. Subsequent sequencing analysis reveals changes in kidney cells after virus infection. The protocol was designed for kidney organoids cultured in a 6-well transwell format but can be adapted to organoids with different organ backgrounds.

Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
Protocol
Using human iPSC-derived kidney organoids to decipher SARS-CoV-2 pathology on single cell level

Katharina C. Reimer,1,2,3,17,* Jitske Jansen,1,4,5 Gijs J. Overheul,6 Pascal Miesen,6 Ronald P. van Rij,6 Sergio H. Triana,7,8,9,10,11 Bart Smeets,4,15,16 Rebekka K. Schneider,2,12,13,14,15 and Rafael Kramann1,3,14,15,16,18,*

1Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany
2Institute of Cell and Tumor Biology, RWTH Aachen University, Aachen, Germany
3Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany
4Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
5Department of Pediatric Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Amalia Children’s Hospital, Nijmegen, the Netherlands
6Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
7Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
8Broad Institute of MIT and Harvard, Cambridge, MA, USA
9Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA
10Department of Chemistry, MIT, Cambridge, MA, USA
11Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
12Department of Developmental Biology, Erasmus Medisch Centrum, Rotterdam, the Netherlands
13Oncode Institute, Erasmus Medisch Centrum, Rotterdam, the Netherlands
14Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medisch Centrum, Rotterdam, the Netherlands
15These authors contributed equally
16Senior author
17Technical contact
18Lead contact
*Correspondence: katharina.reimer@posteo.de (K.C.R.), rkramann@gmx.net (R.K.)
https://doi.org/10.1016/j.xpro.2022.101612

SUMMARY
We describe a protocol for single-cell RNA sequencing of SARS-CoV-2-infected human induced pluripotent stem cell (iPSC)-derived kidney organoids. After inoculation of kidney organoids with virus, we use mechanical and enzymatic disruption to obtain single cell suspensions. Next, we process the organoid-derived cells into sequencing-ready SARS-CoV-2-targeted libraries. Subsequent sequencing analysis reveals changes in kidney cells after virus infection. The protocol was designed for kidney organoids cultured in a 6-well transwell format but can be adapted to organoids with different organ backgrounds. For complete details on the use and execution of this protocol, please refer to Jansen et al. (2022).

BEFORE YOU BEGIN
This protocol describes the inoculation of induced pluripotent stem cell (iPSC)-derived kidney organoids with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent workflow for single cell RNA sequencing. The final product of this protocol is a targeted sequencing-ready single cell library with amplified SARS-CoV-2 sequences. All work involving
infectious SARS-CoV-2 is legally restricted to biosafety level 3 (S3) laboratories around the world. Thus, this protocol describes infection, handling, and processing of kidney organoids and the first steps of library preparation inside an S3 facility until it is safe to leave this area with the samples. The protocol is divided into four steps: steps 1–3 are carried out at an S3 facility, while step 4 can be carried out in an S1 laboratory. The four steps occur in a sequential manner: 1) inoculation of iPSC-derived kidney organoids with SARS-CoV-2 and incubation, 2) mechanical and enzymatic disruption of organoids to obtain single cell solutions, 3) carrying out the first step of the Next GEM v3.1 protocol for single cell sequencing (10x genomics workflow), and 4) generating a targeted sequencing library to retrieve SARS-CoV-2-specific sequences from single cells in addition to the usual v3.1 single cell library. This protocol was specifically designed for iPSC-derived kidney organoids cultured in a 6-well transwell format (Takasato et al., 2016), but can be adapted for organoids of different organ backgrounds. Similarly, this protocol can be adapted for the inoculation with other viruses.

The protocol starts with mature iPSC-derived kidney organoids, cultured until d7+18 according to an adapted, well-established protocol (Takasato et al., 2016). The organoids were kept in a 6-well transwell format with each transwell filter containing 4 organoids consisting of 300,000 cells each at d7+0. The amount of materials, buffers and solutions is calculated for two filters containing four organoids each to generate two libraries for single cell sequencing: control and SARS-CoV-2-exposed organoids. To assess iPSC-derived kidney organoid quality at the beginning of any inoculation experiment, please refer to the troubleshooting section, problem 1. (Figure 1).

Institutional permissions
Human adult skin fibroblasts derived from a healthy volunteer were reprogrammed into iPSCs using the Yamanaka factors (Takahashi and Yamanaka, 2006) by the Stem Cells Technology Center at Radboud University Medical Center (SCTC, Radboud UMC, Nijmegen, The Netherlands). The iPSCs used in the current study were generated from spare materials from a healthy donor, who did consent with the use of such material and did not suffer from kidney disease. The materials have been anonymized and were collected during a time in which no signed informed consent was required.

Gathering equipment needed inside the S3 laboratory

© Timing: Depending on your local S3 laboratory and training, start planning at least two weeks prior to the start of the first experiment

Preparation is crucial when working in an S3 environment. Prior to your first experiment, you should have received extensive training and be authorized to work in an S3 laboratory. You should further check what equipment is available inside the facility and which additional items need to be brought inside for temporary use. Some items and reagents, such as counting chambers or trypan blue, are often permanently available inside an S3 laboratory. Yet, for items and samples that are to be taken
out of the S3 laboratory, a specific decontamination procedure must be in place, possibly involving quarantining any equipment that is hard to decontaminate.

1. See the key resources table and materials and equipment sections for detailed information on items you will need in- and outside of the S3 laboratory.
2. Discuss with your local S3 laboratory manager about availability of equipment and materials in the facility.
3. Prepare cell buffers and solutions freshly on the day of the experiment (timing: 20 min): See materials and equipment section for preparation of the Cell Resuspension buffer, Digestion solution, 10× buffer, and 10× Master Mix.

△ CRITICAL: Ensure that all solutions are kept on ice or at 4°C until use.

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Bacterial and virus strains | SARS-CoV-2, strain BavPat1/2020, titered by plaque assay on Vero E6 cells. | European Virus Archive Global (EVAg) (Varghese et al., 2021) Ref SKU: 026V-03883 |
| Chemicals, peptides, and recombinant proteins | Dulbecco’s Modified Eagle Medium (DMEM)/F-12 | Thermo Fisher Scientific Cat#11320074 |
| | Phosphate buffered saline (PBS) | Fisher Scientific Cat#11503387 |
| | Essential 6 Medium | Thermo Fisher Scientific Cat#A1516401 |
| | Fetal bovine serum (FBS) | Bio&SELL Cat#FBS.GP.0500 |
| | Bovine serum albumin (BSA) | Fisher Scientific Cat#A6964 |
| | DNase I | Sigma-Aldrich Cat#11284932001 |
| | Glycerin (glycerol), 50% (v/v) Aqueous Solution | RICCA Chemical Company Cat#3290-32 |
| | Nuclease-free water | Thermo Fisher Scientific Cat#AM9937 |
| | Trypan Blue Solution 0.4% | Fisher Scientific Cat#15250061 |
| | KAPA Biosystems HiFi HotStart ReadyMix | Roche Cat#7958927001 |
| | Buffer EB | QIAGEN Cat#19086 |
| | AMPure XP beads | Beckman Coulter Cat#A63880 |
| Critical commercial assays | Chromium Next GEM Single Cell 3’ Gel Bead Kit v3.1, 4 nns | 10× Genomics Cat#1000129 |
| | Dual Index Kit TT Set A, 96 nns | 10× Genomics Cat#1000215 |
| | Chromium Next GEM Chip G Single Cell 3’ Kit, 4 nns | 10× Genomics Cat#1000130 |
| | Chromium Next GEM Chip G Single Cell Kit, 16 nns | 10× Genomics Cat#1000127 |
| | Library Construction Kit 4 nns | 10× Genomics Cat#1000196 |
| | Qubit™ dsDNA HS Assay Kit | Thermo Fisher Scientific Cat#Q32851 |
| Experimental models: Cell lines | Kidney organoids derived from Human induced pluripotent stem cell line iP5 15 | Stem Cell Technology Center, Radboud UMC, The Netherlands iP5 15 clone 0001 |
| Oligonucleotides | Partial Read 1 Primer 5’-CTACACGCGTCTCTCCGATCT-3’ (Reverse primer for PCR1 and PCR2 with 10× Genomics, HPLC purified) | (Schraivogel et al., 2020a) N/A |
| | Targeted 10× Primer 5’-AATGATACGGCGACCACTATGGTGACCACTACACATCTTCCCTCTACACGACGCTCTTCCCTCCTATACGACGCTCTTCCTCGAGG-3’ (Forward primer for PCR3 with 10× Genomics, * thioate linkage between last three bases and HPLC purified) | (Schraivogel et al., 2020a) N/A |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Illumina Reverse Primer (N7XX) 5’-CAAGCA GAAGACGGCATACGAGAT [X]8 GTCTCGTG GGTCCTGA-3’ (HPLC purified) | (Schraivogel et al., 2020a) | N/A |
| SARS-CoV-2 Outer Primer 5’-ACCACACAA GCCAGATGGGC-3’ (HPLC purified) | (Triana et al., 2021) | N/A |
| SARS-CoV-2 Inner Primer 5’-GTCTCGTG GCCAGATGGGC-3’ (HPLC purified) | (Triana et al., 2021) | N/A |

Software and algorithms

BioRender (Graphical abstract, Figure 1 and Figure 2 of this paper) | http://biorender.com | N/A |

Other

Corning® Transwell® polyester membrane cell culture inserts, 24 mm Transwell® with 0.4 μm pore polyester membrane inserts, TC-treated, sterile | Sigma-Aldrich | Cat#CLS3450 |

40 μm cell strainers | Corning | Cat#CLS431750 |

50 mL Falcon centrifuge tubes | Thermo Fisher Scientific | Cat#352070 |

200 μl wide-bore pipette tips | Thermo Fisher Scientific | Cat#A-14-222-726 |

Neubauer counting chamber | Carl Roth | Cat#T728.1 |

Haemocytometer coverslips 20 x 26 mm | Carl Roth | Cat#L189.1 |

PCR Tubes 0.2 mL B-tube strips | Eppendorf | Cat#951010022 |

RNaseZAP | Sigma-Aldrich | Cat#R2020 |

Nuclease-free water | Thermo Fisher Scientific | Cat#AM9937 |

6-well plates, tissue-culture-treated | Corning | Cat#3516 |

BD MicroBeads™ 3 Needles, 27G | BD | Cat#302200 |

Qubit™ 4 Fluorometer | Thermo Fisher Scientific | Cat#Q33238 |

Qubit™ Assay Tubes | Thermo Fisher Scientific | Cat#32856 |

10x Magnetic separator | 10x Genomics | Cat#120250 |

Thermal cycler, e.g., C1000 Touch Thermal Cycler with 96-Deep Well Reaction Module | Bio-Rad | Cat#1851197 |

Centrifuge for 50 mL Falcon tubes, e.g., Multifuge X1 Pro | Thermo Fisher Scientific | Cat#75009710 |

Mini centrifuge with PCR tube rotor, e.g., Mini centrifuge ROTILABO® Uni-fuge | Carl Roth | Cat#CX73.1 |

Chromium Next GEM Controller | 10x Genomics | Cat#1000204 |

Chromium Next GEM Secondary Holder | 10x Genomics | Cat#1000142 |

RT Reagent B (included in: Chromium Next GEM Chip G Single Cell 3 Kit, 4 rxns, Cat#1000130) | 10x Genomics | Cat#2000165 |

RT Enzyme C (included in: Chromium Next GEM Chip G Single Cell 3 Kit, 4 rxns, Cat#1000130) | 10x Genomics | Cat#2000102 |

Template Switch Oligo (included in: Chromium Next GEM Chip G Single Cell 3 Kit, 4 rxns, Cat#1000130) | 10x Genomics | Cat#3000228 |

Reducing Agent B (included in: Chromium Next GEM Chip G Single Cell 3 Kit, 4 rxns, Cat#1000130) | 10x Genomics | Cat#2000087 |

Chromium Partitioning Oil, (included in: Chromium Next GEM Chip G & Gaskets, 10x Genomics, Cat#1000127) | 10x Genomics | Cat#2000190 |

Single Cell 3 v3.1 Gel Beads, (included in: Chromium Next GEM Single Cell 3 Gel Bead Kit v3.1, 4 rxns, Cat#1000129) | 10x Genomics | Cat#2000164 |

Chromium Next GEM Chip G, (included in: Chromium Next GEM Chip G & Gaskets, 10x Genomics, Cat#1000127) | 10x Genomics | Cat#2000177 |

Chromium Next GEM Chip G Gasket (included in: Chromium Next GEM Chip G & Gaskets, 10x Genomics, Cat#1000127) | 10x Genomics | Cat#3000072 |
MATERIALS AND EQUIPMENT

| Equipment and materials needed in safety level 1 or 3 laboratories | Safety level 1 | Safety level 3 |
|---------------------------------------------------------------|----------------|----------------|
| Thermal cycler, e.g., C1000 Touch Thermal Cycler with 96-Deep Well Reaction Module, Bio-Rad, Cat#1851197 | yes | yes |
| Centrifuge for 50 mL Falcon tubes, e.g., Multifuge X1 Pro, Thermo Fisher Scientific, Cat#7500710 | no | yes |
| Mini centrifuge with PCR tube rotor, e.g., Mini centrifuge ROTILABO® Uni-fuge, Carl Roth, Cat#OX73.1 | yes | yes |
| Neubauer counting chamber, Carl Roth, Cat#T728.1 | no | yes |
| Hemocytometer coverslips 20 × 26 mm, Carl Roth, Cat#L189.1 | no | yes |
| Inverted microscope, e.g., Primovert, Carl Zeiss, Cat#49126-0001-000 | no | yes |
| 40 μm cell strainers, Corning, Cat#CLS431750 | no | yes |
| 50 mL Falcon centrifuge tubes, Thermo Fisher Scientific, Cat#352070 | no | yes |
| 200 μL wide-bore pipette tips, Thermo Fisher Scientific, Cat#14-222-726 | no | yes |
| PCR Tubes 0.2 mL 8-tube strips, Eppendorf, Cat#951010022 | yes | yes |
| RNaseZAP, Sigma-Aldrich, Cat#R2020 | yes | yes |
| Nuclease-free water, Thermo Fisher Scientific, Cat#AM9937 | no | yes |
| 6-well plate, tissue-culture-treated, Corning, Cat#3516 | no | yes |
| Chromium Next GEM Controller, 10X Genomics, Cat#1000142 | no | yes |
| Chromium Next GEM Secondary Holder, 10X Genomics, Cat#1000142 | no | yes |
| RT Reagent B, 10X Genomics, Cat#2000165 (included in: Chromium Next GEM Chip G Single Cell 3’ Kit, 4 rxns, Cat#1000130) | no | yes |
| RT Enzyme C, 10X Genomics, Cat#2000102 (included in: Chromium Next GEM Chip G Single Cell 3’ Kit, 4 rxns, Cat#1000130) | no | yes |
| Template Switch Oligo, 10X Genomics, Cat#3000228 (included in: Chromium Next GEM Chip G Single Cell 3’ Kit, 4 rxns, Cat#1000130) | no | yes |
| Reducing Agent B, 10X Genomics, Cat#2000087 (included in: Chromium Next GEM Chip G Single Cell 3’ Kit, 4 rxns, Cat#1000130) | no | yes |
| Chromium Partitioning Oil, 10X Genomics, Cat#2000190 (included in: Chromium Next GEM Chip G & Gaskets, 10X Genomics, Cat#1000127) | no | yes |
| Single Cell 3’ v3.1 Gel Beads, 10X Genomics, Cat#2000164 (included in: Chromium Next GEM Chip G & Gaskets, 10X Genomics, Cat#1000127) | no | yes |
| Chromium Next GEM Chip G, 10X Genomics, Cat#2000177 (included in: Chromium Next GEM Chip G & Gaskets, 10X Genomics, Cat#1000127) | no | yes |
| Chromium Next GEM Chip G Gasket, 10X Genomics, Cat#3000072 (included in: Chromium Next GEM Chip G & Gaskets, 10X Genomics, Cat#1000127) | no | yes |
| BD Microlance™ 3 Needles, 27G | no | yes |

Note: Depending on your local S3 laboratory guidelines, removable equipment that cannot be safely decontaminated, such as the chromium controller and the thermocycler, might need to be quarantined for a certain period of time inside the S3 until safe removal is possible.

Digestion solution

| Reagent | Final concentration | Amount |
|---------|---------------------|--------|
| Accutase | 1X, ready to use | 650 μL |
| DNase I | 100 μg/mL | 13 μL |
| Total | | 663 μL |

Prepare freshly on the day of the experiment and store at 4°C for a maximum of 48 h.
This step describes how to inoculate iPSC-derived kidney organoids with SARS-CoV-2 and maintain them in culture for up to 120 h afterward. The work will be conducted in an S3 laboratory and requires a pre-made, titered stock of SARS-CoV-2 as well as mock control, as previously described (Hoffmann et al., 2020). To assess iPSC-derived kidney organoid quality at the beginning of any inoculation experiment, please refer to the troubleshooting section, problem 1.

1. Prepare medium for SARS-CoV-2 inoculation of iPSC-derived kidney organoids.
   a. Prewarm Essential 6 medium to room temperature (18°C–22°C).
   b. Clean a biohazard safety cabinet as well as any small equipment (pipettes, tweezers) with 80% ethanol according to the local standard.
   c. Mix 2 mL of Essential 6 medium with the SARS-CoV-2 stock (titer typically around $1.75 \times 10^7$ PFU/mL but varies from stock to stock) to reach an estimated multiplicity of infection (MOI) of 1.0 per transwell insert. Prepare the same amount of mock medium for the uninfected controls.

   **Note:** To prepare the inoculum at the desired MOI, the number of cells per organoid needs to be established beforehand. We recommend running a pilot dissociation experiment to count the number of cells per organoid for each experimental condition and assume similar numbers in follow-up experiments. This could be carried out by following steps 5–8 of this protocol. The number of cells per organoid obtained in the end corresponds to the number of viral infectious units (PFU, plaque-forming units) that should be used for inoculation to reach an MOI of 1. Details of the virus stock cultivation and titration are described in detail in Varghese et al., 2021.
2. Expose kidney organoids to the SARS-CoV-2 inoculum.
   a. Remove the old medium from below each transwell filter (6-well format) (Figure 2A).

   **Optional:** If you would like to perform a plaque assay to monitor virus replication in the organoids, store the initial organoid medium prior to SARS-CoV-2 inoculation for baseline control measurements at −80°C.

   b. Add new medium per condition: Essential 6 plus SARS-CoV-2 for experiment and Essential 6 containing mock medium for control organoids. Each transwell filter should contain 2 mL of fresh medium: 1.2 mL below the filter, 800 μL on top of the filter (Figure 2B).

   c. Incubate the organoids for 24 h at 37°C, 5% (v/v) CO₂.

3. Remove virus-containing medium from the organoids after 24 h of inoculation with SARS-CoV-2.
   a. Remove the old medium from below and on top of the transwell filter.

   **Optional:** Wash the organoids below and above the filter with 2 mL of PBS (18°C–22°C) both below and on top of the transwell filter. Wash the organoids three times in total.

   b. Remove the PBS and add 1.2 mL of pre-warmed Essential 6 medium to the bottom of the transwell filter. Do not add medium to the top of the filter.

4. Incubation of virus-infected kidney organoids.
   a. Incubate the organoids for 120 h.

   b. Refresh Essential 6 medium every 48 h while keeping the kidney organoids in culture: remove old medium and add 1.2 mL of fresh Essential 6 medium below the transwell filter, no medium on top. Remember to bring the medium to 18°C–22°C before adding it below the filter.

   **Note:** Adding medium on top and below the transwell filter during organoid inoculation with SARS-CoV-2 increases the organoid-virus interaction surface and might thereby enhance the infection efficiency.
Digesting kidney organoid tissue into single cell suspensions

**Timing:** 1 h

This step yields a single cell suspension of organoid-derived cells as input for the single cell sequencing workflow (see Figure 3). We calculated timing and reagents for two transwell filters containing four organoids each: control and SARS-CoV-2-exposed kidney organoids. This step will be conducted in an S3 environment.

5. Prepare the kidney organoids for digestion.
   a. Cool a centrifuge for 50 mL Falcon tubes to 4°C.
   b. Remove organoids from the incubator and remove the medium (Figures 3A and 3B).
   c. Gently wash the organoids on top and below the transwell filter with 2 mL PBS (18–22°C) each. Repeat this step to a total of 3 washes.

6. Mechanic and enzymatic digestion of the organoids.
   a. Remove PBS and add 300 µL of the Digestion Solution (stored at 4°C) containing Accutase and DNase I (see materials and equipment section above) on top of each transwell filter (Figure 3C).
   b. Resuspend and mechanically disrupt the organoids in the Digestion Solution using a 200 µL wide-bore tip with an inner tip diameter of approx. 1 mm (Figure 3C).

**Alternatives:** Instead of fabric-made wide-bore tips you can also use custom-made ones. For this, prepare a box of 200 µL or 1 mL standard pipette tips and cut off the tips at the desired circumference (approximately 1 mm in inner opening diameter). Autoclave prior to use.
c. Transfer the organoid suspension to a new 6-well plate without transwell inserts (Figure 3D).

d. Incubate the cell suspension for 15–18 min at 37°C. During this period, resuspend the organoids by pipetting them up and down 10 times in the same Digestion Solution every 2 min until it becomes a homogeneous single cell suspension (Figure 3E).

7. Stop the enzymatic digestion (Figure 3F).
   a. Place 40 μm cell strainers on top of two 50 mL Falcon tubes and pre-wet the filters with PBS (18°C–22°C).
   b. Add 4 mL of the Stopping Solution (DMEM/F12 + 10% (v/v) FCS) onto each of the two single cell suspensions in the 6-well plate to inactivate accutase and DNase.
   c. Transfer each suspension through a cell strainer. Wash the filter using more Stopping Solution. The volume can go up to 20 mL.
   d. Remove the 40 μm cell strainers and centrifuge the single cell suspensions at 300 × g for 5 min at 4°C.
   e. In the meantime, prepare two new Falcon tubes with 40 μm cell strainers and pre-wet the filters with PBS (18°C–22°C).
   f. Discard the supernatants, resuspend the cell pellets in 1 mL 10× buffer (see materials and equipment section) and filter each through the 40 μm cell strainers. Wash the filters using 20 mL 10× buffer each for maximum cell retrieval.
   g. Remove the 40 μm cell strainers and centrifuge the single cell suspensions at 300 × g for 5 min at 4°C.
   h. Discard the supernatants and resuspend each cell pellet in 500 μL 10× buffer (PBS + 1% BSA).

8. Count the cells (Figures 3G and 3H).
   a. Prepare a Neubauer counting chamber.
   b. Dilute 10 μL of each single cell suspension with 10 μL of trypan blue (1:1).
   c. Place the Neubauer counting chamber under a microscope and count 4 times 16 squares.
   d. Calculate the total cell number according to this equation: total number of cells = [(number of cells per 16 squares)/4] * 2 * 10,000.
   e. Ideally, the cell concentration should be around 1,000 cells/μL for 10× genomics single cell workflow. One expects ca. 4 million cells from four organoids with around 5%–10% of trypan blue positive cells.

   Note: If you experience a high number of trypan blue positive/dead cells, please refer to the troubleshooting section, problem 3, for potential solutions.

9. Keep the single cell suspensions at 4°C and continue directly with step 3: Processing of cells for single cell RNA sequencing.

   Note: Although described in the context of single cell RNA sequencing workup at an S3 laboratory, the organoid dissociation step of the protocol can be utilized for a manifold of applications including fluorescence-activated cell scanning (FACS) and sorting.

   Note: Should your single cell suspension show aggregates and clumps (visible cell aggregates in the Neubauer counting chamber), please refer to the troubleshooting section, problem 2, for potential solutions.

Processing cells for single-cell RNA sequencing

© Timing: 2 h

This step uses the single cell suspensions retrieved in the previous step of this protocol as input for the first step of the Next GEM v3.1 single cell sequencing workflow (10× genomics). The steps follow the original manufacturer’s protocol Chromium Next GEM Single Cell 3’ v3.1 (Dual Index) User Guide Rev C) and end with an incubation step in a thermal cycler that also serves to inactivate the
virus, allowing transfer of the samples from the S3 laboratory for further processing. It is strongly recommended to familiarize oneself with the Next GEM v3.1 protocol before continuing. Here, we provide a brief recapitulation of step 1 of the Next GEM v3.1 workflow for two samples: control and SARS-CoV-2-infected.

10. Clean a laboratory bench RNA or biochemistry working area with 80% ethanol and an RNase-eliminating agent, e.g., RNase-Zap.

11. Prepare reagents and the 10× Master Mix solution.
   a. Bring the Next GEM beads to 18°C–22°C. Vortex for 30 s and spin down briefly directly before use.
   b. Keep RT Reagent B, Template Switch Oligo, and Reducing Agent B to 18°C–22°C.
   c. Keep RT Enzyme C at 4°C until use.
   d. Prepare 10× Master Mix for two samples (see materials and equipment section) at 4°C in a PCR tube.

12. Prepare Chromium Chip G.
   a. Place Chip G into its secondary holder.
   b. Fill unused wells on a Chip G with 50% glycerol according to the manufacturer’s protocol (Chromium Next GEM Single Cell 3’ v3.1 (Dual Index) User Guide Rev C, page 28, step 1.2a): 70 μL into each unused well in row 1, 50 μL into each unused well in row 2, and 45 μL in each unused well in row 3.
   c. This protocol will load two samples onto the chip, thus 6 reactions remain unused.

13. Load samples onto Chromium Chip G.
   a. Mix cells, nuclease-free water, and 10× Master Mix according to the manufacturer’s table. For a concentration of 1000 cells/μL and a targeted cell number of 10,000, this means mixing the following components per sample: 31.9 μL 10× Master Mix, 16.5 μL cell suspension, and 26.7 μL nuclease-free water. Mix well by pipetting 15 times without introducing air bubbles.
   b. Load 70 μL of Cell-Master-Mix into each sample row 1 on the chip.
   c. Add 50 μL of 10× beads into each sample row 2 on the chip.
   d. Add 40 μL of partitioning oil into each sample row 3 on the chip.

   **Note:** Carefully check for air bubbles in any of the wells before applying the gasket and placing the chip into the chromium controller. If you spot air bubbles, remove them with the help of a needle. Remaining air bubbles in any of the wells may cause wetting failure and loss of sample.

14. Attach the 10× gasket and place the chip and secondary holder into the chromium controller.
   a. Run the chromium controller Chip G programme. This will take 17 min 42 s.
   b. After completion of the chromium controller run, slowly and carefully transfer the products into new PCR tubes.
   c. Put the two PCR tubes containing the control and the SARS-CoV-2-exposed sample into a thermocycler and run the following programme:

| Thermocycler conditions (total run time: ~55 min) |
|-----------------------------------------------|
| **Steps** | **Temperature** | **Time** | **Cycles** |
| 1         | 53°C           | 45 min   | 1         |
| 2         | 85°C           | 5 min    | 1         |
| Hold      | 4°C            | Forever  |           |
| Lid temp  | 53°C           | Volume: 125 μL |           |
Preparation of targeted libraries to computationally retrieve SARS-CoV-2 content in single cells

© Timing: 6 h

This step guides you through the generation of a SARS-CoV-2-targeted library in parallel to the usual library construction process within the 10x genomics Next GEM v3.1 single cell RNA sequencing workflow. The starting point of this step is single-cell barcoded cDNA (step 2 of the Chromium Next GEM Single Cell 3' v3.1 (Dual Index) User Guide Rev C). Thus, you will first have to generate cDNA from the samples of the previous step according to the manufacturer’s protocol (= step 2) before continuing with the library. The aim is to generate a SARS-CoV-2-targeted library, in addition to the standard 10x V3.1 library construction workflow (Schraivogel et al., 2020a, 2020b; Triana et al., 2021). This targeted library is generated by two PCS amplifications of SARS-CoV2 specific primers and a final indexing PCR (PCR 1–3) (Figure 4A). Both libraries are finally sequenced together, to later on computationally map the targeted and amplified SARS-CoV-2 reads to the individual cells of the single cell RNA sequencing library. Further detailed information on the steps of this part of the protocol is described in the original protocol (Schraivogel et al., 2020b).

15. Carry out step 2 of the Chromium Next GEM Single Cell 3' v3.1 (Dual Index) User Guide Rev C protocol provided by 10x Genomics (https://support.10xgenomics.com/permalink/3qX8xY2MpoCLCpum4Whp49) to generate cDNA from the samples of the previous step before continuing the preparation of the SARS-CoV-2-targeted library (Timing: ~2 h plus quality control of the cDNA, e.g., by Agilent Bioanalyzer).
16. Use the resulting cDNA from step 18 as input for PCR1 and pipette PCR reaction master mix 1 on ice. Pipet mix or vortex well.

**PCR reaction master mix 1**

| Reagent                        | Amount for 1 sample |
|--------------------------------|---------------------|
| amplified cDNA                 | 10 ng               |
| Kapa Hif                       | 50 µL               |
| 10 µM Partial Read 1 Primer    | 4 µL                |
| 100 µM SARS-CoV-2 Outer Primer | 2.5 µL              |
| ddH₂O                          | add ddH₂O up to a total assay volume of 100 µL |

17. Run PCR 1 with the following PCR 1 cycling conditions:

**PCR 1 cycling conditions**

| Steps         | Temperature | Time | Cycles |
|---------------|-------------|------|--------|
| Initial Denaturation | 98°C        | 3 min | 1      |
| Denaturation   | 98°C        | 20 s  | 11 cycles |
| Annealing     | 67°C        | 60 s  |        |
| Extension     | 72°C        | 60 s  |        |
| Final extension | 72°C       | 5 min | 1      |
| Hold          | 4°C         |      | Hold   |

18. Once the run is finished, collect the tube and spin down briefly.

19. Post PCR cleanup with AMPure size selection beads, selecting for DNA fragments greater than 150 base pairs.
   a. Add 150 µL of AMPure beads to your PCR 1 product and pipette mix 15 times. Incubate at 18°C–22°C for 5 min.
   b. Place the tube into a 10× magnetic separator at the High position and wait until the solution clears. This usually takes 1–2 min.
   c. Remove the supernatant and add 300 µL of 80% ethanol. Wait 30 s.
   d. Remove the ethanol and wash the sample again two times with 200 µL 80% ethanol for 30 s each.
   e. Remove the ethanol, centrifuge the tube briefly, place it back in the 10× magnetic separator at the Low position, remove the remaining ethanol and air-dry the beads for max. 2 min.
   f. Elute the product by adding 30.5 µL of EB buffer. Pipet mix 15 times and incubate the solution for 2 min at 18°C–22°C.
   g. Place the tube in the 10× magnetic separator at the Low position and wait for the solution to clear.
   h. Transfer 30 µL of the cleared solution into a new PCR tube strip. Use 1 µL thereof for concentration measurement with the Qubit dsDNA HS Kit. The expected amount of PCR product produced with PCR 1 lies between 10 to 250 ng.

20. Prepare PCR 2 by using 10 ng of the PCR 1 product as input for PCR 2 and pipette PCR reaction master mix 2 on ice. Pipet mix or vortex well.

**PCR reaction master mix 2**

| Reagent                        | Amount for 1 sample |
|--------------------------------|---------------------|
| PCR1 product                   | 10 ng               |
| Kapa Hif                       | 50 µL               |
| 10 µM Partial Read 1 Primer    | 4 µL                |
| 100 µM SARS-CoV-2 Inner Primer | 2.5 µL              |
| ddH₂O                          | add ddH₂O up to a total assay volume of 100 µL |
21. Run PCR 2 with the following PCR 2 cycling conditions:

| Steps            | Temperature | Time   | Cycles |
|------------------|-------------|--------|--------|
| Initial Denaturation | 98°C        | 3 min  | 1      |
| Denaturation      | 98°C        | 20 s   | 7 cycles |
| Annealing         | 67°C        | 60 s   |        |
| Extension         | 72°C        | 60 s   |        |
| Final extension   | 72°C        | 5 min  | 1      |
| Hold              | 4°C         |        |        |

22. Once the run is finished, collect the tube and spin down briefly.

23. Post PCR cleanup with AMPure size selection beads, selecting for DNA fragments greater than 150 base pairs.
   a. Add 150 μL of AMPure beads to your PCR 2 product and pipette mix 15 times. Incubate at 18°C–22°C for 5 min.
   b. Place the tube into a 10× magnetic separator at the “high position” and wait until the solution clears. This usually takes 1–2 min.
   c. Remove the supernatant and add 300 μL of 80% ethanol. Wait 30 s.
   d. Remove the ethanol and wash the sample again two times with 200 μL 80% ethanol for 30 s each.
   e. Remove the ethanol, centrifuge the tube briefly, place it back in the 10× magnetic separator at the Low position, remove remaining ethanol and air-dry the beads for max. 2 min.
   f. Elute the product by adding 30.5 μL of EB buffer. Pipet mix 15 times and incubate the solution for 2 min at 18°C–22°C.
   g. Place the tube in the 10× magnetic separator at the “low position” and wait for the solution to clear.
   h. Transfer 30 μL of the cleared solution into a new tube strip. Use 1 μL thereof for concentration measurement with the Qubit dsDNA HS Kit. The expected amount of PCR product lies within 10–100 ng.

24. Prepare PCR 3 by using 10 ng of the PCR 2 product as input for PCR 3 and pipette PCR reaction master mix 3 on ice. Pipet mix or vortex well.

| PCR reaction master mix 3 |
|---------------------------|
| Reagent                   | Amount for 1 sample |
| PCR2 product              | 10 ng               |
| Kapa Hifi                 | 50 μL               |
| 10 μM Targeted 10X Primer | 4 μL                |
| 10 μM N70X Primer         | 2.5 μL              |
| ddH2O                     | add ddH2O up to a total assay volume of 100 μL |

25. Run PCR 3 with the following PCR 3 cycling conditions:

| Steps            | Temperature | Time   | Cycles |
|------------------|-------------|--------|--------|
| Initial Denaturation | 98°C        | 3 min  | 1      |
| Denaturation      | 98°C        | 20 s   | 7 cycles |
| Annealing         | 67°C        | 60 s   |        |
| Extension         | 72°C        | 60 s   |        |
| Final extension   | 72°C        | 5 min  | 1      |
| Hold              | 4°C         |        |        |
26. Once the run is finished, collect the tube and spin down briefly.
27. Post PCR cleanup with AMPure size selection beads, selecting for DNA fragments greater than 150 base pairs.
   a. Add 150 μL of AMPure beads to your PCR 3 product and pipette mix 15 times. Incubate at 18°C–22°C for 5 min.
   b. Place the tube into a 10× magnetic separator at the “high position” and wait until the solution clears. This usually takes 1–2 min.
   c. Remove the supernatant and add 300 μL of 80% ethanol. Wait 30 s.
   d. Remove the ethanol and wash the sample again two times with 200 μL 80% ethanol for 30 s each.
   e. Remove the ethanol, centrifuge the tube briefly, place it back in the 10× magnetic separator at the “Low position”, remove remaining ethanol and air-dry the beads for max. 2 min.
   f. Elute the product by adding 30.5 μL of EB buffer. Pipet mix 15 times and incubate the solution for 2 min at 18°C–22°C.
   g. Place the tube in the 10× magnetic separator at the “low position” and wait for the solution to clear.
   h. Transfer 30 μL of the cleared solution into a new tube strip. Use 1 μL thereof for concentration measurement with the Qubit dsDNA HS Kit. Before sequencing, the PCR 3 product should be quality controlled, e.g., with an Agilent Bioanalyzer.
28. The product of PCR 3 is an Illumina sequencing-ready library that should be sequenced in one run together with a standard 10× Genomics Next GEM v3.1 library (step 3 - library construction - of the manufacturer's protocol) generated of the same cDNA as the SARS-CoV-2-targeted library was generated from. Alternatively, it can be run on its own but PhiX spike-in should be used to increase sequence diversity. The expected outcome lies within the 100 ng range.

**EXPECTED OUTCOMES**

This protocol aims to provide a comprehensive workflow from an iPSC-derived kidney organoid SARS-CoV-2 infection model to a sequencing-ready Illumina library within the 10× genomics pipeline. By implementing the generation of a SARS-CoV-2-targeted library, single cell identity and infection status can be matched computationally.

In the end, a standard 10× v 3.1 single cell library will be sequenced together with the targeted library. Both libraries were generated from the same cDNA. Before sequencing, both libraries will undergo quality control, e.g., with an Agilent Bioanalyzer. Example bioanalyzer traces for both the standard 10× genomics Next GEM version 3.1 library (Figure 4B) and the SARS-CoV-2 targeted library (Figure 4C) are shown in Figure 4.

**LIMITATIONS**

Dissociating iPSC-derived kidney organoids into single cells is critical for various workflows, including single cell RNA sequencing. For mechanical and enzymatic disruption of the organoid tissue, timing is critical. Overexposing the delicate organoid tissue to the enzymes, i.e., if handling takes longer than expected, cell viability is hampered. In the context of infection models of SARS-CoV-2, the workflows at an S3 facility add several layers of complexity to this process, as S3 lab specific safety measures increase time needed per step which should be considered when planning the experiments.

iPSC-derived kidney organoids harbor many cell types present in the adult kidney, including proximal tubular cells and podocytes. However, the maturity of the organoids is closer to a second trimester fetal kidney than the adult organ. Organoids generally contain a certain number of off-target cells that naturally are not present at the same percentage in the adult organ. These might influence infection rates and experimental outcome, e.g., when off-target cells are more susceptible to inoculation with a certain pathogen than the focused cell types. This should be considered when planning infection experiments as it might be limiting the explanatory power in an adult disease.
Single cell RNA sequencing data is sparse so absence of a gene from the sequence data does not mean that the gene is not expressed. We recommend using an orthogonal method to check for expression of the mRNA such as single molecule fluorescence in situ hybridization, in addition.

**TROUBLESHOOTING**

**Problem 1**
There are few to no structures present in my kidney organoids. Is it worth to proceed? This problem is related to the section before you begin and to step 1 of this protocol.

**Potential solution**
Input organoid quality is essential for a reliable outcome of the inoculation experiments. It is therefore essential to subject iPSC-derived kidney organoids to a thorough quality assessment before beginning the actual experiment. We recommend to at least check for maintenance of steady structure presence three consecutive days before starting the inoculation with SARS-CoV-2. This can easily be done by eye, using an optical microscope. Alternatively, especially if the desired read-out relies on the expression of certain genes, transporters or similar, it is recommended to check for expression of respective genes by PCR. In the case of SARS-CoV-2 inoculation, we e.g., checked for ACE2 expression in the iPSC-derived kidney organoids prior to the start of the experiments, as ACE2 is one of the main SARS-CoV-2 cell entry factors.

**Problem 2**
The organoids do not dissociate well and/or cell aggregates show in the single cell suspension. This problem may occur during or after digestion of the organoids (steps 6 and 7).

**Potential solution**
For the downstream single cell RNA sequencing workflow, it is crucial to obtain clean single cell suspensions without cell aggregations, as these may cause clogs with subsequent wetting failure in the delicate microfluidic system of the Chromium Next GEM chip and controller. Suboptimal dissociation of organoids during the digestion procedure can be resolved by more careful resuspension. One could also try a normal 1 mL pipette tip (smaller diameter than the wide-bore tip) for resuspension a few minutes into the process to aid taking organoid pieces apart. However, do not exceed the overall digestion time to longer than 18 min as this increases cell death rates.

Cell aggregates within the single cell suspension are commonly caused by surrounding debris and free DNA originating from dead or dying cells. The problem can be resolved by carefully resuspending the cell suspension, thereby disruption the aggregates. Alternatively, passing the cell solution through another 40 or 30 μm cell strainer might help, but will also decrease cell yield. DNase I, which is part of the Digestion Solution, also helps with degrading extracellular DNA, minimizing the risk of cell aggregate formation after digestion. If DNase I was added already and you experience cell aggregates nonetheless, the concentration of the enzyme can be doubled.

**Problem 3**
The amount of trypan blue positive dead or dying cells is very high (>20%). This problem may occur after counting the cells post digestion (step 8 of this protocol).

**Potential solution**
A high amount of dead and/or dying cells is impeding a favorable outcome after single cell RNA sequencing. Unfortunately, the options for dead cell removal might be very limited in an S3 laboratory, e.g., sorting to remove the dead cells is likely not available. Our protocol is designed to result in as little as 5%–10% dead or dying cells after accutase digestion. Make sure that all cell solutions are always kept at 4°C, except during accutase digestion, and process all samples as quickly as possible. Handling and processing quickly are key. Be sure you are well trained on the protocol before going to the S3 laboratory. Depending on the kind of organoids you use, other digestion enzymes, such as
collagenase or liberase, might give better results than accutase. It might help to have a backup set of organoids ready for another try if the digestion time was exceeded. Another option would be the use of a dead cell removal kit (e.g., Miltenyi Biotec, catalog number 130-090-101). However, the latter procedure will add approximately 30 min to the total processing time, potentially decreasing live cell number even further.

Problem 4
The amount of PCR product after PCR 1, 2 or 3 is very low. This problem refers to steps 19h, 23h and/or 27h.

Potential solution
The expected yield of PCR product lies between 10 and 250 ng for PCR 1, between 10 and 100 ng for PCR 2, and around 100 ng for PCR 3. If the amount is lower than this, it is recommended to increase the number of cycles respectively for PCR 1, 2 or 3. Overall, the amount of PCR product is dependent on the sample, the cell number, and the number of PCR cycles. If increasing cycle number >16 does not lead to significant increase of PCR product, the problem is likely rooted in the sample input at the beginning of the TAPseq protocol. A potential solution might be to increase the sample input.

Problem 5
The amount of PCR product after PCR 1, 2 or 3 is very high. This problem refers to steps 19 h, 23 h and/or 27 h.

Potential solution
The expected yield of PCR product lies between 10 and 250 ng for PCR 1, between 10 and 100 ng for PCR 2, and around 100 ng for PCR 3. If the amount is, however, higher than the expected range, this could lead to higher molecular weight products (around 1.000–1.5000 base pairs). We have not experienced this in our hand, but it was described previously that this might lead to inefficient clustering during Illumina run preparation (Schraivogel et al., 2020b). The suggested solution is to decrease cycle numbers by 1–2.

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Rafael Kramann, MD, PhD (rkramann@gmx.net).

Materials availability
This study did not generate new unique reagents. For specific details on availability please refer to the key resources table.

Data and code availability
This protocol did not generate/analyze datasets or code.

ACKNOWLEDGMENTS
This work was supported by grants of the German Research Foundation (DFG: KR 4073/11-1; SFBTRR219, 322900939; and CRU344, 428857858, and CRU5011 InterakD 445703531), a grant of the European Research Council (ERC-StG 677448), the Federal Ministry of Research and Education (BMBF NUM-COVID19, Organo-Strat 01KX2021), the Dutch Kidney Foundation (DKF) TASK FORCE consortium (CP1805), the Else Kroener Fresenius Foundation (2017_A144), and the ERA-CVD MENDAGE consortium (BMBF 01KL1907) all to R.K.; DFG (CRU344 P2 to R.K.S.); and the BMBF eMed Consortium Fibromap (to R.K., and R.K.S.). R.K.S. received support from the KWF Kankerbestrijding (11031/2017–1, Bas Mulder Award) and a grant by the ERC (deFiber; ERC-StG 757339). J.J. is supported by the Netherlands Organization for Scientific Research (NWO Veni grant no: 091 501 61 81 01 36) and the DKF (grant no. 19OK005). B.S. is supported by the DKF.
(grant: 14A3D104) and the NWO (VIDI grant: 016.156.363). R.P.V.R. and G.J.O. are supported by the NWO VICI (grant: 16.VICI.170.090).

AUTHOR CONTRIBUTIONS
K.C.R. and J.J. conceptualized the study and conducted the experiments. K.C.R. designed the figures and wrote the manuscript. J.J., G.O., P.M., R.P.v.R., S.H.T., B.S., R.K.S., and R.K. edited the manuscript. J.J., R.P.v.R., B.S., R.K.S., and R.K. acquired funding.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Hoffmann, M., Mösbauer, K., Hofmann-Winkler, H., Kaul, A., Kleine-Weber, H., Krüger, N., Gassen, N.C., Müller, M.A., Drosten, C., and Pöhlmann, S. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588–590.

Jansen, J., Reimer, K.C., Nagai, J.S., Varghese, F.S., Overheul, G.J., de Beer, M., Röverts, R., Daviran, D., Ferrin, L.A.S., Willemse, B., et al. (2022). SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell 29, 217–231.e8.

Schraivogel, D., Gschwind, A.R., Milbank, J.H., Leonce, D.R., Jakob, P., Mathur, L., Korbel, J.O., Merten, C.A., Velten, L., and Steinmetz, L.M. (2020a). Targeted Perturb-seq enables genome-scale genetic screens in single cells. Nat. Methods 17, 629–635.

Schraivogel, D., Velten, L., Gschwind, A.R., and Steinmetz, L.M. (2020b). A protocol for targeted perturb (TAP)-seq and targeted single-cell RNA-seq (Protocol Exchange). https://protocolexchange.researchsquare.com/article/pex-864/v1.

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676.

Takasato, M., Er, P.X., Chiu, H.S., and Little, M.H. (2016). Generation of kidney organoids from human pluripotent stem cells. Nat. Protoc. 11, 1681–1692.

Triana, S., Metz-Zumaran, C., Ramirez, C., Kee, C., Doldan, P., Shahraz, M., Schraivogel, D., Gschwind, A.R., Sharma, A.K., Steinmetz, L.M., et al. (2021). Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut. Mol. Syst. Biol. 17, e10232.

Varghese, F.S., van Woudenbergh, E., Overheul, G.J., Eleved, M.J., Kurev, L., van Heerbeek, N., van Laarhoven, A., Miesen, P., den Hartog, G., de Jonge, M.I., and van Rij, R.P. (2021). Berberine and obatoclax inhibit SARS-Cov-2 replication in primary human nasal epithelial cells in vitro. Viruses 13, 282.